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Background: Hospitalization of patients with opioid use disorder (OUD) is increasing, yet little is 49 
known about opioid agonist therapy (OAT: methadone and buprenorphine) administration 50 
during admission.  51 
 52 
Objective: Describe and examine patient-and hospital-level characteristics associated with OAT 53 
receipt during hospitalization in the Veterans Health Administration (VHA).  54 
 55 
Participants: 12,407 unique patients, ≥ 18 years old, with an OUD-related ICD-10 diagnosis 56 
within 12 months prior to or during index hospitalization in fiscal year 2017 from 109 VHA 57 
hospitals in the continental United States. 58 
 59 
Main Measure: OAT received during hospitalization. 60 
 61 
Key Results: Few admissions received OAT (n = 1,914; 15%) and when provided it was most 62 
often for withdrawal management (n = 834; 7%). Among patients not on OAT prior to admission 63 
who survived hospitalization (n = 10,969), 2.0% (n = 203) were newly initiated on OAT with 64 
linkage to care after hospital discharge. Hospitals varied in the frequency of OAT delivery (range 65 
0% to 43% of qualified admissions). Patients with pre-admission OAT (Adjusted Odds Ratio 66 
[AOR] = 15.30; 95% CI [13.2, 17.7]), acute OUD diagnosis (AOR = 2.3; 95% CI [1.99, 2.66]), and 67 
male gender (AOR 1.52; 95% CI [1.16, 2.01]) had increased odds of OAT receipt. Patients who 68 
received non-OAT opioids (AOR 0.53; 95 CI [0.46, 0.61]) or surgical procedures (AOR 0.75; 95 CI 69 
[0.57, 0.99]) had decreased odds of OAT receipt. Large (AOR = 2.0; 95% CI [1.39, 3.00]) and 70 
medium-sized (AOR = 1.9; 95% CI [1.33, 2.70]) hospitals were more likely to provide OAT. 71 
 72 
Conclusions: In a sample of VHA inpatient medical admissions, OAT delivery was infrequent, 73 
varied across the health system, and was associated with specific patient and hospital 74 
characteristics. Policy and educational interventions should promote hospital-based OAT 75 
delivery. 76 




Surging opioid-related hospitalizations challenge the acute care delivery system in the 79 
United States (U.S.).1 Opioid-related hospitalizations are associated with increased 80 
readmissions2 and 12% of patients admitted with an OUD-related condition leave the hospital 81 
against medical advice.3 OUD-related admissions disproportionately burden public payers3,4 and 82 
cost more than non-opioid-related admissions.3,5 Opioid agonist therapy (OAT)—buprenorphine 83 
or methadone6—are provided infrequently and variably during hospitalization7 or upon 84 
discharge.8 Underutilization occurs although OAT delivery during hospitalization is feasible9,10 85 
and OAT receipt is associated with decreased illicit opioid use upon discharge,9 reduced 30 and 86 
90-day readmissions, 11 and increased post-hospital substance use disorder (SUD) treatment 87 
engagement.11,12  88 
 Veterans are particularly vulnerable as they are twice as likely to die from accidental 89 
opioid overdose than non-veterans.13 OUD diagnoses within the Veterans Health 90 
Administration (VHA) have increased by nearly two-fold between 2004 (n = 30,093)14 and 2017 91 
(n = 54,078).15 The VHA’s initiatives to increase OAT access16 include a system-wide 92 
requirement that all VHA facilities provide access to OAT16 and follow national OUD treatment 93 
guidelines.17 In fiscal year 2017, 41% (n = 22,179) of VHA patients with OUD received an OUD-94 
related pharmacotherapy.15 At the facility-level, OUD-related pharmacotherapy delivery ranged 95 
from 2% to 76% across the VHA system.15 To date, little is known about inpatient practice for 96 
this patient population. This multi-hospital retrospective study examines variation in OAT 97 





Study Design and Cohort 101 
A retrospective sample of unique acute medical and surgical inpatient admissions from 102 
fiscal year 2017 was extracted from the VHA Corporate Data Warehouse, a database containing 103 
national VHA patient electronic health record data. Eligible individuals were aged 18 or older 104 
with a primary or secondary OUD ICD-10 diagnosis from any source (inpatient, outpatient, and 105 
community care paid for by VHA) in the year preceding index hospitalization or during index 106 
hospitalization in fiscal year 2017. Facilities were restricted to “acute care hospitals” with at 107 
least 500 acute bed days of care delivered during the study period and at least 25 index 108 
admissions. Patients were excluded if they did not have a primary or secondary admission code, 109 
if they had an Elixhauser cancer flag,18 and if they had a hospital length of stay (LOS) within the 110 
99th percentile (median 82 days, range 51 to 1,652 days). The 99% percentile LOS cutoff was 111 
chosen to capture those admitted with OUD-related infections warranting 4 to 6 weeks of 112 
inpatient antibiotics and to exclude chronic hospitalization. See Figure 1. The Veterans Affairs 113 
Portland Health Care System Institutional Review Board approved this study (# 4045). 114 
Study Variables 115 
 Variable selection and construction were informed by the existing literature, data 116 
availability, and prior qualitative research.19,20 Study variables included patient demographics 117 
(age, gender, race, ethnicity), patient diagnoses present on admission (co-occurring mental 118 
health and SUD diagnoses), admission characteristics (intensive care unit [ICU] or surgical 119 
services received), and admission-related diagnoses (OUD-related infection, OUD-related 120 
diagnoses). Hospital characteristics included admission volume, acute OUD diagnosis volume 121 
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(the percentage of admissions with an acute OUD diagnosis during hospitalization), hospital 122 
geographic location, and hospital size. 123 
Pharmacotherapy variables were coded for three time periods: 1) 30 days pre-124 
admission; 2) during admission; and 3) 30 days post-admission. Non-OAT pharmacotherapy 125 
included benzodiazepines, non-OAT opioids (e.g., oxycodone), naltrexone, naloxone, inpatient 126 
use of first-line opioid withdrawal adjuvant (clonidine), and second-line withdrawal adjuvants 127 
(baclofen, gabapentin/pregabalin, tizanidine). See Appendix Table 1 for additional details. 128 
Admission OAT was categorized by four OAT delivery scenarios (OAT continued, OAT initiated 129 
with linkage to care, OAT for withdrawal, and OAT sustained), see Table 1. Categories and 130 
calculations involving post-admission care excluded patients who died during admission. 131 
Statistical Analysis 132 
RStudio21-27 was used for descriptive statistics and bivariate analyses. Multilevel logistic 133 
regression modeling used Stata28 with an alpha value of 0.05. The dependent variable (level 1) 134 
was any OAT received (yes/no) during hospitalization, and covariates were level 1 (patient) and 135 
level 2 (hospital) continuous, binary, or categorical variables. See Appendix Table 2 for model 136 
covariates. Covariate inclusion was based on literature review, study aims, and model fit. 137 
Comparative model fit for nested models used the log-likelihood ratio test, the Akaike 138 
Information Criterion, and the Bayesian Information Criterion. Regression coefficients, standard 139 
errors, adjusted odds ratios (AOR) with 95% confidence intervals, and the intraclass correlation 140 
coefficient (ICC) were reported. A sensitivity analysis examined whether a narrower OAT 141 






Patient Characteristics. The study cohort included 12,407 unique patients with index 146 
hospitalizations from 109 VHA acute care hospitals in the continental U.S. Most patients were 147 
male (n = 11,543; 93%), white (n = 8,880; 72%) or Black (n = 2,706; 22%), and non-Hispanic or 148 
Latino (n = 11,476; 93%) with a median age of 61 years (range 21 to 90). Over half of patients (n 149 
= 8,094; 65%) had at least one co-occurring mental health diagnosis and nearly half had at least 150 
one co-occurring SUD diagnosis (n = 6,024; 49%).  151 
Admission-Related Characteristics. The median length of hospital stay was 5 days 152 
(range 1 to 50 days). Nearly 20% of patients (n = 2,303) received ICU services and 6% (n = 779) 153 
received surgical services. OUD-related infection or primary or secondary OUD-related 154 
diagnoses occurred in 20% of admissions (n = 2,491) and 1% of patients died during admission 155 
(n = 119).  156 
 Pre-and-Post-Pharmacotherapy. Approximately one in ten patients received OAT in the 157 
30 days prior to admission (n = 1,325; 11.5%) and in the 30 days post hospital discharge (n = 158 
1,420; 11.6%). Thirty percent of patients (n = 3,766) had an opioid prescription filled in the 30 159 
days before admission and 35% (n = 4,250) filled an opioid prescription in the 30 days after 160 
discharge.  161 
 Admission Pharmacotherapy. The majority of patients did not receive OAT during 162 
admission (n = 10,493; 85%). In the 15% of admissions with OAT (n = 1,914), methadone was 163 
more common (n = 1,049; 55%) than buprenorphine (n = 639; 33%). A small number of patients 164 
(n = 136; 7.1%) received more than one type of OAT and 4.7% (n = 90) had non-specific 165 
administration. For patients on OAT prior to admission (n = 1,325), 65% (n = 867) had their OAT 166 
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continued during admission and 35% (n = 458) had their OAT discontinued during admission—167 
regardless of receipt post-admission. 168 
 Related to withdrawal management, 9% of patients received the VHA’s recommended 169 
first line adjuvant for opioid withdrawal—clonidine—and 39% (n = 1,089) received a second-170 
line adjuvant (baclofen, gabapentin/pregabalin, or tizanidine).29 Over half of patients (55%; n = 171 
6,765) received at least one non-OAT opioid (e.g., oxycodone) during admission. 172 
 Hospital OAT by Delivery Scenario. When hospital OAT was delivered for patients not 173 
on pre-admission OAT it was most often provided as withdrawal management (n = 834; 44%) 174 
and infrequently initiated during hospitalization with linkage to care upon discharge (n = 203; 175 
11%). For patients on pre-admission OAT, it was most often delivered as a sustained medication 176 
(n = 722; 38%)—OAT received before, during, and after admission—and less often continued 177 
during admission, but with subsequent discontinuation after discharge (n = 140; 8%). See Table 178 
2 for additional details on patient and admission-related characteristics and pharmacotherapy. 179 
 System-Wide OAT Delivery. Across the 109 VHA hospitals, the median OAT delivery 180 
frequency during admission was 11% (SD: 0.10; range 0% to 43%). The data had a non-normal 181 
distribution skewed towards less OAT delivery, see Figure 2. The frequency of OAT delivery 182 
scenario in each hospital varied. For example, two hospitals did not provide any OAT, and 183 
nearly half of hospitals (48%, n = 52) did not have a single admission in which OAT was initiated 184 
with linkage to care (range 0 to 16 admissions). Measures of variation (ICC) are reported in 185 





Hospital and Patient-Level Associations with OAT Receipt 189 
Patient-Level Covariates. In the fully specified model, 13 covariates were associated 190 
with hospital OAT receipt. Six covariates increased the odds of receiving OAT during 191 
hospitalization: pre-admission OAT receipt (AOR 15.3; 95% CI [13.2, 17.7]); an OUD diagnosis or 192 
OUD-related infection during admission (AOR 2.30; 95% CI [1.99, 2.66]); male gender (AOR 193 
1.52; 95% CI [1.16, 2.01]); receipt of adjuvant medication for opioid withdrawal during 194 
admission (AOR 1.52; 95% CI [1.32, 1.75]); an opioid withdrawal diagnosis (AOR 1.47; 95% CI 195 
[1.12, 1.92]); and an increased length of hospital stay (AOR 1.04; 95% CI [1.03, 1.05]). Seven 196 
covariates were associated with decreased odds of OAT receipt: the receipt of pre-admission 197 
naltrexone (AOR 0.26; 95% CI [0.12, 0.56]); an unintentional overdose diagnosis (AOR: 0.29; 198 
95% CI [0.16, 0.52]); the receipt of admission naltrexone (AOR 0.31; 95% CI [0.14, 0.66]); pre-199 
admission non-OAT opioid receipt (AOR 0.49; 95% CI [0.41, 0.58]); non-OAT opioid receipt 200 
during admission (AOR 0.53; 95 CI [0.46, 0.61]); surgical service receipt during admission (AOR 201 
0.75; 95 CI [0.57, 0.99]); and having a co-occurring SUD diagnosis (AOR: 0.77; 95% CI [0.67, 202 
0.88]). See Appendix Table 4. 203 
Hospital-Level Covariates. Four hospital-level covariates were associated with hospital 204 
OAT receipt. Patients admitted to large (AOR 2.04; 95% CI [1.39, 3.00]) and medium-sized 205 
hospitals (AOR 1.90; 95% CI [1.33, 2.70]) had increased odds of OAT receipt compared with 206 
small hospitals. Patients admitted to hospitals located in the northeast (AOR 1.80; 95% CI [1.30, 207 
2.49]) and west (AOR 1.62; 95% CI [1.19, 2.22]) had increased odds of OAT receipt compared 208 
with those in the south. See Table 3 for the fully-specified model output. 209 
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Sensitivity Analysis. A pre-specified sensitivity analysis examined if a narrower OAT 210 
definition would change study findings; specifically, removing non-FDA approved formulations 211 
of OAT for the treatment of OUD (e.g., injectable methadone) from the admission OAT variable. 212 
In this sensitivity analysis surgical service received during admission was no longer statistically 213 
significant. No other differences were observed in statistical significance or the directionality of 214 
the relationships between covariates and the primary outcome. See Appendix Table 5. 215 
Discussion 216 
This retrospective cohort analysis of 12,407 VHA hospitalized individuals with a past 217 
year or admission-related ICD-10 OUD diagnosis suggests that hospital OAT receipt was rare. 218 
This study is the first to examine hospital OAT delivery across multiple hospitals. A limited 219 
research base has examined hospital OAT delivery. A ten-year (2004 to 2014) retrospective 220 
chart review of patients with intravenous drug use associated infective endocarditis—from a 221 
single Massachusetts hospital—observed that only 11% of OUD admissions received OAT.7 Our 222 
national study confirms and expands upon these findings. Only 15% of patients in our study 223 
received any OAT during admission (n = 1,914) and the vast majority (91%) of patients not on 224 
OAT prior to admission did not receive any OAT during hospitalization (n = 10,035). 225 
Further, only 203 patients in our cohort were initiated on OAT and subsequently linked 226 
to care—a nationally recommend best-practice.6,30 Instead most patients (80%) were provided 227 
opioid withdrawal management, representing a missed opportunity to continue OUD treatment 228 
beyond hospitalization. Moreover, hospital admission interrupted ongoing outpatient OUD 229 
treatment. Over a third of patients had their outpatient OAT discontinued during admission. 230 
Contemporary guidance strongly recommends continuing outpatient OAT during admission, 231 
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including for patients who are undergoing surgical procedures.6,31 It is possible that evolving 232 
practice recommendations were not reflected in our sample. Anesthesiologists may 233 
recommend buprenorphine discontinuation prior to surgery. However, only 6% of our cohort 234 
received surgery and only 12% of those patients were on OAT prior to admission; thus, it is 235 
unlikely that this is driving observed findings. Moreover, OAT discontinuation during admission 236 
may reflect challenges related to care transitions.20  237 
Previous research in the VHA describes system wide-variation in OUD-related 238 
pharmacotherapy delivery, which ranged from 2% to 76% of qualified patients per facility.15 239 
That analysis, however, did not examine variation specifically for hospital admissions. Our study 240 
aligns with and builds upon these prior findings. We observed OAT delivery frequency per 241 
hospital ranging from 0% to 43% of qualified admissions. 242 
 Prior VHA research suggests that specific patient characteristics are positively associated 243 
with OAT receipt including male gender, age 56 years or older, and those without a co-244 
occurring mental health diagnosis.32 Gender disparities in SUD treatment and engagement have 245 
been described in other care delivery settings.33 Our study builds upon these findings, 246 
suggesting that women-identified patients may be less likely to receive OAT during 247 
hospitalization. Associations from this study also suggest that outpatient OAT preceding 248 
hospitalization influences subsequent hospital OAT delivery, highlighting the importance of OAT 249 
engagement prior to admission. Further, specific care received during admission decreased OAT 250 
receipt; for example, patients who received non-OAT opioids or surgical procedures were less 251 
likely to receive OAT during hospitalization. These two clinical scenarios should not influence 252 
hospital OAT administration. Finally, immutable hospital characteristics (e.g., size and location) 253 
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influenced OAT delivery, and may reflect unmeasurable internal hospital attributes (e.g., 254 
resources or culture).20 These findings could also reflect the contribution of elements outside 255 
the hospital, for example, local beliefs about addiction and availability of community-based 256 
treatment resources.20 257 
Study Limitations 258 
This is an observational, unmatched, retrospective cohort study; thus, causal 259 
relationships cannot be established. There are limitations to the generalizability of study 260 
findings because of the cohort (Veterans, older, white, mostly men) and the health system 261 
setting (VHA); however, given that the VHA is an integrated health system that has prioritized 262 
OAT delivery, it is possible that VHA OAT delivery outperforms non-VHA hospitals. We elected 263 
to include patients with an OUD diagnosis in the prior year, not just patients with an admission 264 
diagnosis; thus, for 80% of patients OUD was not the primary reason for hospitalization. The 265 
pragmatic study sample selection may be seen as a limitation, but we believe reflects the 266 
realities of acute care delivery for patients hospitalized with complications related to OUD and 267 
other chronic illnesses. Patients in our cohort may have been misclassified with an OUD 268 
diagnosis and thus were not valid OAT candidates. The challenges of using diagnosis-based 269 
denominators for cross-facility comparisons are discussed elsewhere.34 Conversely, OUD is also 270 
underdiagnosed and eligible patients may have been inadvertently excluded. Further, our study 271 
only includes VHA pharmacotherapy data; thus, it is possible that patients received OAT after 272 
discharge at a non-VHA facility. However, this is unlikely to significantly influence our results 273 
because there were only six cases with post-admission non-VHA OAT receipt in the original data 274 
extraction. Another study limitation was our inability to discern why OAT was not delivered 275 
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(e.g., patients may have declined OAT). Finally, the study data are from 2017, a specific moment 276 
in time that does not capture potential changes in practice over time. 277 
Implications for Practice, Research, and Policy 278 
 The findings from this study may motivate practice improvement, future research, and 279 
inform policy to increase hospital-based OAT delivery in the midst of the opioid-related 280 
overdose crisis. 281 
 Practice Improvement. National authorities recommend OAT continuation or initiation 282 
in the hospital6 and a National Academies of Science, Engineering, & Medicine consensus report 283 
concluded that: “Withholding or failing to have available all classes of FDA-approved 284 
medication for the treatment of opioid use disorder in any care or criminal justice setting is 285 
denying appropriate medical treatment”(p.3).30 Further, hospitalization is a reachable moment 286 
for treatment initiation and engagement.35,36 Unfortunately, our study suggests that hospital 287 
OAT delivery frequency may be far from optimal. Current practice is not only a missed 288 
opportunity for treatment engagement, but may also cause harm by disrupting life-saving care. 289 
A recent systematic review suggests that the provision of addiction-related services for 290 
hospitalized patients with OUD improves patient, provider, and health care outcomes.37 291 
Interventions to improve OAT delivery may include an organizational intervention—the 292 
addiction consult service (ACS), which provides clinical, educational, and policy-based addiction 293 
services and programming in the hospital.38 ACSs, however, are unlikely to be available or 294 
feasible across all hospitals. Further, it is likely that many hospital providers have limited 295 
addiction training39 and are less confident in providing OAT and delivering other OUD-related 296 
services. To address this issue, the VHA and other national hospital authorities could publish 297 
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specific guidance promoting evidence-based addictions hospital care40 or create educational 298 
campaigns encouraging hospital-based OAT delivery. These initiatives would likely need to 299 
address provider knowledge gaps and addiction-related stigma,20,41 describe pathways to OAT 300 
after discharge, and identify policies impeding care inside and outside the hospital-setting.20  301 
Future Research. Research should explore barriers to OAT initiation during 302 
hospitalization at the VHA, and reasons for practice variation at patient, hospital, and system 303 
levels. Given the VHA’s prioritization of OUD treatment, it is possible that the VHA may be 304 
outperforming non-VHA hospitals. Future research may confirm this impression. Policymakers 305 
and researchers need to consider data access issues. One of the primary challenges to studying 306 
hospital OAT delivery is the widespread use of diagnosis-related groupings (DRG) in hospital 307 
billing. DRG allows hospitals to bill payers through a bundled payment algorithm to account for 308 
illness acuity.42 Study replication using Medicaid claims data, for example, is not feasible 309 
because most admission-related medications are not captured in the bundled claims data.  310 
 Policy Interventions. The VHA has already mandated national standards to enhance 311 
services for patients with OUD. Additional policy interventions outside the VHA may be 312 
warranted. Policies requiring all hospitals to offer OAT could be leveraged through hospital-313 
related accrediting bodies (e.g., the Joint Commission). At present, there are no accreditation 314 
requirements related to hospital care for persons with OUD and SUDs. It is within the authority 315 
of the Joint Commission to require reporting and performance measurement for OAT and to 316 
mandate addiction-related technologies for hospital accreditation (e.g., presence of addiction 317 
physicians or ACS). Another approach is local legislation. In August 2018, the Massachusetts 318 
legislature passed House Bill 4866, Prevention and Access to Appropriate Care and Treatment of 319 
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Addiction,43which requires Massachusetts’ emergency departments to offer OAT for patients 320 
with an opioid overdose and to link them to outpatient services.43 Similar policies could be 321 
created for inpatient service delivery. Finally, there is interest in reforming restrictive federal 322 
OAT policies, specifically, to abolish buprenorphine x-waiver requirements.44 323 
Conclusions 324 
In a retrospective, unmatched pragmatic VHA patient cohort, hospital OAT delivery 325 
varied widely, was infrequently delivered, and was most commonly administered as a 326 
continued outpatient medication or for withdrawal management. These findings are the first 327 
multisite description of hospital OAT delivery and reveal characteristics that require further 328 
exploration to understand how to increase OAT access to patients hospitalized with OUD.  329 
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Table 1. Hospital OAT Delivery by Scenario 
Variable Pharmacotherapy 
Any OAT Received Any OAT received during admission 
OAT Continuation OAT received during pre-admission and admission, but not post-admission 
OAT Initiation & Linkage to Care OAT received during admission and post-admission, but not pre-admission 
OAT Sustained OAT received pre-admission, during admission and post-admission 
OAT Withdrawal OAT received during admission, but not pre or post-admission 
Table Notes. OAT = opioid agonist therapy; Pre-Admission OAT: VHA OTP visit or Healthcare Common Procedure 
Coding System (HCPCS) codes (H0033; J0574; J0575; J0571; S0109) or outpatient buprenorphine filled 
prescriptions: buprenorphine film buccal; buprenorphine sublingual tablet; buprenorphine/naloxone film 
sublingual; buprenorphine/naloxone sublingual tablet; Admission OAT: VHA OTP visit or HCPCS codes (H0033; 
J0571; S0109) or any formulation of buprenorphine or methadone administered: buprenorphine sublingual 
tablet; buprenorphine/naloxone sublingual film; buprenorphine/naloxone sublingual tablet; buprenorphine 
injection; buprenorphine patch; methadone injection; methadone solution concentrate; methadone solution oral; 
methadone tablet; methadone tablet effervescent; and methadone unknown formulation; Post-admission OAT: 
VHA OTP visit or HCPCS codes (H0033; J0574; J0575; J0571; S0109) or outpatient buprenorphine filled 
prescriptions: buprenorphine film buccal; buprenorphine sublingual tablet; buprenorphine/naloxone film 
















Table 2. Patient, Admission, and Hospital Characteristics 
Variable Frequency % Count  
Patient Characteristics (n = 12,407) 
Age Median 61; Mean 58.5  
Range 21 to 90 
Gender  
Male  93.0% (11,543) 
Female 6.8% (864) 
Race  
American Indian or Alaska Native 1.2% (147) 
Asian <1% (43) 
Black or African American 21.8% (2,706) 
Native Hawaiian or Pacific Islander < 1% (106) 
White 71.6% (8,880) 
Unknown/Declined to Answer 4.2% (525) 
Ethnicity  
Hispanic or Latino 4.8% (595) 
Non-Hispanic or Latino 92.5% (11,476) 
Unknown 2.7% (336) 
Co-Occurring Mental Health Diagnosis  65.2% (8,094) 
Co-Occurring Substance Use Disorder Diagnosis 48.6% (6,024) 
Co-Occurring Mental Health and Substance Use Disorder Diagnoses 41.0% (5,091) 
Admission-Related Characteristics (n = 12,407) 
Length of Stay Median, 5; Mean 6.6 
Range 1 to 50 
Admission Source  
Outpatient Treatment 49.1% (6,095) 
Other Direct Admission 45.3% (5,616) 
Other 4.9% (696) 
Services Received  
ICU Services 18.6% (2,303) 
Surgical Services 6.3% (779) 
Acute OUD Infection Diagnosis 5.5% (691) 
OUD-Related Diagnosis Primary and/or Secondary 14.9% (1,848) 
OUD-Related Diagnosis and/or Acute OUD Infection 20.1% (2,491) 
Pre-Admission Pharmacotherapy (n = 12,407) 
No OAT Received 89.3% (11,082) 
Pre-Admission OATa 10.7% (1,325) 
Buprenorphine Onlyb 5.0% (625) 
Non-Specific Administrationc 4.7% (577) 
>1 Type of OAT Receivedd <1% (112) 
Methadone Onlye <1% (11) 
Non-OAT Opioid Prescription Filled 30.4% (3,766) 
Naltrexone Received or Prescription Filled 2.0% (244) 
Naloxone Prescription Filled 3.8% (477) 
Admission Pharmacotherapy (n = 12,407) 
No OAT Received 84.6% (10,493) 
Admission OATa  15.4% (1,914) 
Methadone Onlye 8.5% (1,049) 
Buprenorphine Onlyb 5.2% (639) 
>1 Type of OAT Receivedd 1.1% (136) 
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Non-Specific Administration Onlyc <1% (90) 
Any Withdrawal Adjuvants 44.4% (5,502) 
First-Line Adjuvant—Clonidine 8.8% (1,089) 
Second-Line Adjuvant—Baclofen, Gabapentin/Pregabalin, or Tizanidine 39.3% (4,882) 
Both Adjuvants 3.4% (469) 
Non-OAT Opioid Received 54.5% (6,765) 
Naltrexone Received  1.4% (168) 
Post-Admission Pharmacotherapyf (n = 12, 288) 
No OAT Received 88.4% (10,868) 
Post-Admission OATa 11.6% (1,420) 
Buprenorphine Onlyb 5.2% (633) 
Non-Specific Administration Onlyc 5.1% (628) 
>1 Type of OAT Receivedd 1.2% (142) 
Methadone Onlye <1% (17) 
Non-OAT Opioid Prescription Filled 34.6% (4,250) 
Naltrexone Received or Prescription Filled 2.8% (341) 
Naloxone Prescription Filled 6.2% (765) 
Hospital OAT Delivery by Scenariof (n = 12, 288) 
OAT for Withdrawal Management 6.8% (834) 
OAT Sustained 5.9% (722) 
OAT Initiated with Linkage to Care 1.7% (203) 
OAT Continued 1.2% (140) 
Secondary Outcomes 
Left Hospital Against Medical Advicef 5.7% (701) 
In-Hospital Mortality  1.0% (119) 
Pre-OAT Received <1% (6) 
Pre-OAT Not Received 1.0% (113) 
Death within 30 Days of Dischargef <1% (110) 
Emergency Department Visit within 30 Days of Dischargef 27.9% (3,434) 
Hospital Readmission within 30 Days of Dischargef 13.3% (1,630) 
Hospital Characteristics (n = 109) 
Hospital Size 
Small: 1 to 49 beds 25.7% (28) 
Medium: 50 to 99 beds 33.0% (36) 
Large: ≥100 beds 41.3% (45) 
Hospital Region  
Midwest 22.9% (25) 
Northeast 16.5% (18) 
South 39.4% (43) 
West 21.1% (23) 
Admission Volume Median 98; Mean 114 
Range 26 to 430; IQR 97                              
Acute OUD Relative Volume Median 32% 
Range 13% to 83% 
Table Notes. ICU = intensive care unit; OUD = opioid use disorder; OAT = opioid agonist therapy; IQR = 
interquartile range; aIncludes each of the 4 sub-categories in this table; bIncludes buprenorphine prescription 
fills and the Healthcare Common Procedure Coding System (HCPCS) codes J0574, J0575, J0571; cIncludes an 
OTP stop code visit or the non-specific OAT administration HCPCS code H0033; dIncludes any patients 
who received more than one type of OAT during the pre-period; eIncludes the methadone specific HCPCS 
code S0109; fPercentage and count excludes 119 inpatient deaths (n = 12, 288); If a medication was used 








Table 3. Multilevel Logistic Regression Model: Hospital OAT Delivery 
Parameters B SE AOR 95% CI 
Intercept -2.78*** 0.00 0.04 0.03 0.13 
Patient-Level Covariates 
Age 0.00 0.08 1.00 1.00 1.01 
Gender: Male (ref. Female) 0.42** 0.18 1.52 1.16 2.01 
Race: Non-white (ref. White) -0.05 0.14 0.95 0.82 1.11 
Race: Unknown (ref. White) -0.18 0.21 0.84 0.59 1.19 
Ethnicity: Hispanic (ref. Non-Hispanic) 0.02 0.07 1.02 0.77 1.34 
Ethnicity: Unknown (ref. Non-Hispanic) 0.17 0.07 1.2- 0.80 1.81 
Acute OUD Diagnosis/Infection 0.83*** 0.07 2.30 1.99 2.66 
Co-Occurring Substance Use Disorder Diagnosis -0.26*** 0.30 0.77 0.67 0.88 
Co-Occurring Mental Health Diagnosis -0.04 0.14 0.97 0.84 1.11 
Unintentional Overdose Diagnosis During Admission -1.24*** 0.00 0.29 0.16 0.52 
Opioid Withdrawal Diagnosis During Admission 0.38** 0.08 1.47 1.12 1.92 
Hospital Length of Stay 0.04*** 0.14 1.04 1.03 1.05 
ICU Services Received During Admission -0.13 0.14 0.88 0.74 1.03 
Surgical Services Received During Admission -0.29* 0.08 0.75 0.57 0.99 
Pre-Admission OAT Received 2.73*** 0.12 15.3 13.1 17.7 
Pre-Admission Non-OAT Opioid Prescription Filled -0.72*** 0.38 0.49 0.41 0.58 
Pre-Admission Benzodiazepine Prescription Filled 0.03 0.08 1.03 0.81 1.32 
Pre-Admission Naltrexone Received or Prescription Filled -1.33*** 0.00 0.26 0.12 0.56 
Pre-Admission Gabapentin/Pregabalin Prescription Filled -0.12 0.14 0.89 0.77 1.04 
Admission Source: Other (ref. Outpatient) -0.13 0.07 0.88 0.66 1.16 
Admission Source: Direct (ref. Outpatient) -0.01 0.07 0.99 0.85 1.15 
During Admission Non-OAT Opioid Received -0.64*** 0.07 0.53 0.46 0.61 
During Admission Adjuvant Received 0.42*** 0.39 1.52 1.32 1.75 
During Admission Benzodiazepine Received -0.08 0.08 0.92 0.80 1.06 
During Admission Naltrexone Received -1.17** 0.09 0.31 0.14 0.66 
Hospital-Level Covariates 
Acute OUD Diagnoses Volumea -0.02** 0.01 0.98 0.97 0.99 
Hospital Size: Medium (ref. Small) 0.64*** 0.18 1.90 1.33 2.70 
Hospital Size: Large (ref. Small) 0.71*** 0.20 2.04 1.39 3.00 
Census Region: Midwest (ref. South) 0.24 0.16 1.27 0.93 1.72 
Census Region: Northeast (ref. South) 0.59*** 0.17 1.80 1.30 2.49 
Census Region: West (ref. South) 0.48** 0.16 1.62 1.19 2.22 
Admission Volume 0.00 0.00 1.00 1.00 1.00 
Table Notes. Bold indicates statistical significance; p < 0.05*; p < 0.01**; p < 0.001***; aThis relatively 
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Appendix Table 1: Study Variable Definitions 534 
Variable Definition 
Patient Demographics 
OUD ICD-10 Codes 
Queried 
F11.10, F11.11, F11.120 F11.121, F11.122, F11.129, F11.14, F11.150, 
F11.151, F11.159, F11.181, F11.182, F11.188, F11.19, F11.20, F11.220, 
F11.21, F11.221, F11.222, F11.229, F11.23, F11.24, F11.250, F11.251, 
F11.259, F11.281, F11.282, F11.288, F11.29, F11.90, F11.920, F11.921, 
F11.922, F11.929. F11.93, F11.94, F11.950, F11.951, F11.959, F11.981, 
F11.982, F11.988, F11.99, T40.0X1A, T40.0X1D, T40.0X1S, T40.0X4A, 
T40.0X4D, T40.0X4S, T40.0X5A, T40.0X5D, T40.0X5S, T40.1X1A, T40.1X1D, 
T40.1X1S, T40.1X4A, T40.1X4D, T40.1X4S, T40.2X1A, T40.2X1D, T40.2X1S, 
T40.2X4A, T40.2X4D, T40.2X4S, T40.2X5A, T40.2X5D, T40.2X5S, T40.3X1A, 
T40.3X1D, T40.3X1S, T40.3X4A, T40.3X4D, T40.3X4S, T40.3X5A, T40.3X5D, 
T40.3X5S, T40.4X1A, T40.4X1D, T40.4X1S, T40.4X4A, T40.4X4D, T40.4X4S, 
T40.4X5A, T40.4X5D, T40.4X5S, T40.601A, T40.601D, T40.601S, T40.604A, 
T40.604D, T40.604S, T40.605A, T40.605D, T40.605S, T40.691A, T40.691D, 
T40.691S, T40.694A, T40.694D, T40.694S,T40.695A,T40.695D, T40.695S 
Age Age in years present on admission.  
Co-Occurring Mental 
Health Diagnosis1 
Conditions were identified within 365 days prior to the index hospitalization 
admission date: 1) Adjustment Disorder Other; 2) Anxiety Disorder; 3) Mood 
Disorder; 4) Non-Mood Psychotic disorder; 5) PTSD; 6) Self-Harm. Could 




Conditions were identified within 365 days prior to the index hospitalization 
admission date: 1) Alcohol Use Disorder; 2) Cannabis Use Disorder; 3) 
Cocaine Use Disorder; 4) Hallucinogen Use Disorder; 5) Nicotine 
Dependence; 6) Other Psychoactive Use Disorders; 7) Other Stimulant 
Related Disorders; 8) Other Substance Use Disorder; 9) Sedative Hypnotic 
Disorders. Could include more than one. Codes available upon request. 
Gender Male or Female. 
Ethnicity 1) Not Hispanic or Latino; 2) Hispanic or Latino; 3) Unknown. 
OUD-Related 
Diagnosis2 
Primary or secondary ICD-10 OUD admission diagnosis codes. Codes 
available upon request. 
OUD-Related 
Infections2 
Primary or secondary ICD-10 OUD admission diagnosis codes: 1) 
Endocarditis; 2) Candida Endocarditis; 3) Osteomyelitis; 4) Bacteremia; 5) 
Discitis; 6) Septic Arthritis; 7) Brain Abscess; 8) Joint Infection; 9) Necrotizing 
Fasciitis; 10) Empyema; and 11) Lung Abscess. Codes available upon request. 
OUD-Related Diagnosis 
or Infection  
Combined variable: OUD-Related Diagnosis or OUD-Related Infection 
Diagnosis. 
Primary Diagnosis2 The primary ICD-10 admission diagnosis code for index hospitalization. 
Race 1) American Indian or Alaska Native; 2) Asian; 3) Black or African American; 
4) White; 5) Native Hawaiian or Other Pacific Islander; 6) Unknown/Decline 
to Answer. 
Secondary Diagnosis2 The secondary ICD-10 admission diagnosis code for index hospitalization. 
Admission Source Point of admission for the index hospitalization: 1) Outpatient Treatment;  
2) Other Direct Admission; 3) Other. 
Intensive Care Unit 
Service 
Use of intensive care unit services during index hospitalization.  
Length of Stay Length of time (days) of the index hospitalization. 





Benzodiazepine Prescription filled for any benzodiazepine. 
Gabapentin/Pregabalin Prescription filled for gabapentin and/or pregabalin.  
Naloxone Prescription filled for naloxone. 
Naltrexone Prescription filled or HCPCS code for naltrexone. 
Opioid  Prescription filled for any non-OAT opioids, not including methadone or 
buprenorphine. 
Admission3  
Benzodiazepine Administration of benzodiazepine. 
Gabapentin/Pregabalin Administration of gabapentin and/or pregabalin. 
Naltrexone Administration of naltrexone. 
Opioid  Administration of any non-OAT opioid, did not include methadone or 
buprenorphine formulations for pain. 
First-Line Withdrawal 
Adjuvant 
Administration of clonidine. 
Second-Line 
Withdrawal Adjuvant4 
Administration of any second-line adjuvant: baclofen or gabapentin or 
pregabalin or tizanidine. Could include more than one. 
Any Withdrawal 
Adjuvants 
Administration of any of the adjuvants: baclofen or clonidine or gabapentin 
or pregabalin or tizanidine. Could include more than one. 
Both Adjuvants Administration of both first-line and second-line withdrawal adjuvants. 
Post-Admission  
Benzodiazepine Prescription filled for any benzodiazepine. 
Gabapentin/Pregabalin Prescription filled for gabapentin and/or pregabalin.  
Naloxone Prescription filled for naloxone. 
Naltrexone Prescription filled or HCPCS code for naltrexone. 
Secondary Outcomes  
In-Hospital Mortality Death during index admission 
Left Against Medical 
Advice 
Leaving against medical advice during admission, collapsed VHA internal 
codes. 
Death Death within the post-admission time period.  
Emergency 
Department Visit 
VHA emergency department visit within the post-admission time period. 




Acute OUD Diagnosis 
Volume 
The proportion of index admissions in a facility with an acute OUD diagnosis 
(OUD-infection or OUD diagnosis). 
Admission Volume The number of admissions in a facility. 
Hospital Region U.S. Census categories: 1) Northeast; 2) Midwest; 3) South; 4) West. 
Hospital Size 1) Small: 1 to 49 beds; 2) Medium: 50 to 99 beds; 3) Large: ≥ 100. 
Table Notes. 1Present on admission = identified within prior 365 days; 2Occurred during admission; 
3During admission < 1% of pharmaceutical data points were prescribed; 4Second line adjuvants are 
medications recommended for use by VHA Opioid Taper Tool; HCPCS = Healthcare Common Procedure 










Appendix Table 2: Model Covariates 542 
Level 1: Patient and Admission Characteristics Level 2: Hospital Characteristics 
Demographics 1. Admission Volume (continuous) 
1. Age (continuous) 2. Acute OUD Diagnoses Relative Volume (continuous) 
2. Male (ref. Female) 3. Hospital Size: Medium (ref. Small) 
3. Race: Non-white (ref. White) 4. Hospital Size: Large (ref. Small) 
4. Race: Unknown (ref. White) 5. Census Region: Midwest (ref. South) 
5. Ethnicity: Hispanic (ref. Non-Hispanic)  6. Census Region: Northeast (ref. South) 
6. Ethnicity: Unknown (ref. Non-Hispanic) 7. Census Region: West (ref. South) 
7. Acute OUD Diagnosis/Infection (yes/no)  
8. Co-occurring Substance Use Disorder Diagnosis (yes/no)  
9. Co-occurring Mental Health Diagnosis (yes/no)  
Admission  
10. Unintentional Overdose Diagnosis (yes/no)  
11. Opioid Withdrawal Diagnosis (yes/no)  
12. Length of Stay (continuous)  
13. ICU Services Received (yes/no)  
14. Surgical Services Received (yes/no)  
15. Admission Source: Other (ref. Outpatient)  
16. Admission Source: Direct (ref. Outpatient)  
17. Opioid Received (yes/no)  
18. Adjuvant Received (yes/no)  
19. Benzodiazepine Received (yes/no)  
20. Naltrexone Received (yes/no)  
Pre-Admission  
21. OAT Received or Prescription Filled (yes/no)  
22. Non-OAT Opioid Prescription Filled (yes/no)  
23. Benzodiazepine Prescription Filled (yes/no)  
24. Naltrexone Received or Prescription Filled (yes/no)  






















Appendix Table 3: Testing for Variation in Hospital OAT Delivery Across the VHA 
 Model 1:  
Without Covariates 
Model 2:  
Patient Covariates 
Model 3:  
Patient and Hospital 
Covariates 
B SE 95% CI B SE 95% CI B SE 95% CI 
Constant 0.52 0.09 0.37, 0.72 0.38 0.07 0.26, 0.56 0.02 0.05 0.13, 0.34 








































































Appendix Table 4: Logistic Regression Models Testing for  
Multilevel Characteristic Associations with Hospital OAT Delivery 
 Model 2: Patient Covariates Model 3: Patient/Hospital 
Covariates 
B SE OR 95% CI B SE OR 95% CI 
Intercept -2.79*** 0.22 0.06 0.04 0.09 -2.78*** 0.00 0.04 0.03 0.13 
Patient-Level Covariates 
Age 0.00 0.00 1.00 1.00 1.01 0.00 0.08 1.00 1.00 1.01 
Gender: Male (ref. Female) 0.42** 0.14 1.52 1.15 2.00 0.42** 0.18 1.52 1.16 2.01 
Race: Non-white (ref. White) -0.07 0.08 0.94 0.80 1.09 -0.05 0.14 0.95 0.82 1.11 
Race: Unknown (ref. White) -0.17 0.18 0.85 0.60 1.20 -0.18 0.21 0.84 0.59 1.19 
Ethnicity: Hispanic (ref. Non-Hispanic) 0.06 0.14 1.06 0.80 1.41 0.02 0.07 1.02 0.77 1.34 
Ethnicity: Unknown (ref. Non-Hispanic) 0.18 0.21 1.20 0.79 1.80 0.17 0.07 1.2- 0.80 1.81 
Acute OUD Diagnosis/Infection 0.83*** 0.07 2.30 1.99 2.67 0.83*** 0.07 2.30 1.99 2.66 
Co-Occurring SUD Diagnosis -0.26*** 0.07 0.77 0.67 0.88 -0.26*** 0.30 0.77 0.67 0.88 
Co-Occurring Mental Health Diagnosis -0.04 0.07 0.96 0.84 1.11 -0.04 0.14 0.97 0.84 1.11 
Unintentional Overdose Diagnosis During Admission -1.24*** 0.30 0.29 0.16 0.52 -1.24*** 0.00 0.29 0.16 0.52 
Opioid Withdrawal Diagnosis During Admission 0.38** 0.14 1.46 1.12 1.91 0.38** 0.08 1.47 1.12 1.92 
Length of Stay 0.04*** 0.00 1.04 1.04 1.05 0.04*** 0.14 1.04 1.03 1.05 
ICU Services Received During Admission -0.12 0.08 0.88 0.75 1.04 -0.13 0.14 0.88 0.74 1.03 
Surgical Services Received During Admission -0.27 0.14 0.76 0.58 1.00 -0.29* 0.08 0.75 0.57 0.99 
Pre-Admission OAT Received 2.73*** 0.08 15.3 13.2 17.8 2.73*** 0.12 15.3 13.1 17.7 
Pre-Admission Non-OAT Opioid Prescription Filled -0.72*** 0.09 0.49 0.41 0.58 -0.72*** 0.38 0.49 0.41 0.58 
Pre-Admission Benzodiazepine Prescription Filled   0.04 0.12 1.04 0.81 1.32 0.03 0.08 1.03 0.81 1.32 
Pre-Admission Naltrexone Received or Filled -1.31** 0.38 0.27 0.13 0.57 -1.33*** 0.00 0.26 0.12 0.56 
Pre-Admission Gabapentin/Pregabalin Prescription Filled  -0.12 0.08 0.89 0.76 1.03 -0.12 0.14 0.89 0.77 1.04 
Admission Source: Other (ref. Outpatient) -0.16 0.14 0.85 0.64 1.12 -0.13 0.07 0.88 0.66 1.16 
Admission Source: Direct (ref. Outpatient) -0.01 0.08 0.99 0.85 1.16 -0.01 0.07 0.99 0.85 1.15 
During Admission Non-OAT Opioid Received -0.63*** 0.07 0.53 0.46 0.61 -0.64*** 0.07 0.53 0.46 0.61 
During Admission Adjuvant Received 0.42*** 0.07 1.53 1.33 1.76 0.42*** 0.39 1.52 1.32 1.75 
During Admission Benzodiazepine Received -0.11 0.07 0.90 0.78 1.04 -0.08 0.08 0.92 0.80 1.06 
During Admission Naltrexone Received -1.19** 0.39 0.30 0.14 0.65 -1.17** 0.09 0.31 0.14 0.66 
Hospital-Level Covariates 
Acute OUD Diagnoses Volume -- -- -- -- -- -0.02** 0.01 0.98 0.97 0.99 
Hospital Size: Medium (ref. Small) -- -- -- -- -- 0.64*** 0.18 1.90 1.33 2.70 
Hospital Size: Large (ref. Small) -- -- -- -- -- 0.71*** 0.20 2.04 1.39 3.00 
Census Region: Midwest (ref. South) -- -- -- -- -- 0.24 0.16 1.27 0.93 1.72 
Census Region: Northeast (ref. South) -- -- -- -- -- 0.59*** 0.17 1.80 1.30 2.49 
Census Region: West (ref. South) -- -- -- -- -- 0.48** 0.16 1.62 1.19 2.22 
Admission Volume -- -- -- -- -- 0.00 0.00 1.00 1.00 1.00 
Table Notes. Bold indicates statistical significance; p < 0.05*; p < 0.01**; p < 0.001*** 
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Appendix Table 5: Sensitivity Analysis: OAT Definition 630 
The multilevel model was run using a narrower OAT definition for admission delivery which excluded any 631 
non-FDA approved versions of OAT (i.e., injectable formulations of methadone and buprenorphine).  632 
 633 
Model 1: The Variance Component Model. There were no differences observed for the narrower OAT 634 
definition. The coefficient was the same and in the same direction. 635 
 636 
Model 2: The Intermediate Model with Level 1 Covariates. There were no differences in the intermediate 637 
model with regards to covariate direction or statistically significant associations, except for the surgical 638 
variable, which was statistically significant in the model presented in the manuscript with the broader OAT 639 
definition. 640 
 641 
Model 3: The Full Model with Level 1 and Level 2 Covariates. There were no differences in the final model 642 
with regards to covariate direction or statistically significant associations, except for the surgical services 643 
received variable, which was statistically significant in the model presented in the manuscript with the 644 
broader OAT definition. 645 
 
Model 3: Narrower OAT Definition 
 OR SE Z P 95% CI  
Intercept 0.06 0.0234484 -7.2 0.0000 0.03 0.13 
Age 1.00 0.002539 0.12 0.9060 1.00 1.01 
Gender: Male (ref. Female) 1.50 0.2121659 2.89 0.0040 1.14 1.98 
Race: Non-white (ref. White) 0.95 0.0738042 -0.71 0.4770 0.81 1.10 
Race: Unknown (ref. White) 0.84 0.149254 -0.98 0.3260 0.59 1.19 
Ethnicity: Hispanic  0.98 0.1419715 -0.11 0.9120 0.74 1.31 
Ethnicity: Unknown 1.20 0.24997 0.88 0.3780 0.80 1.81 
Acute OUD Diagnosis/Infection 2.30 0.1720454 11.12 0.0000 1.99 2.66 
Co-Occurring Substance Use Disorder Diagnosis 0.78 0.0543631 -3.59 0.0000 0.68 0.89 
Co-Occurring Mental Health Diagnosis 0.95 0.0677582 -0.67 0.5050 0.83 1.10 
Unintentional Overdose Diagnosis During Admission 0.27 0.0836167 -4.23 0.0000 0.15 0.50 
Opioid Withdrawal Diagnosis During Admission 1.51 0.206946 3 0.0030 1.15 1.97 
Hospital Length of Stay 1.04 0.0045775 9.69 0.0000 1.03 1.05 
ICU Services Received During Admission 0.89 0.0745036 -1.4 0.1610 0.75 1.05 
Surgical Services Received During Admission 0.77 0.1058284 -1.93 0.0540 0.58 1.00 
Admission Source: Other (ref. Outpatient) 0.88 0.1260072 -0.89 0.3740 0.67 1.17 
Admission Source: Direct (ref. Outpatient) 0.98 0.0771065 -0.22 0.8260 0.84 1.15 
During Admission Non-OAT Opioid Received 0.54 0.0376208 -8.84 0.0000 0.47 0.62 
During Admission Adjuvant Received 1.51 0.1087461 5.79 0.0000 1.32 1.74 
During Admission Benzodiazepine Received 0.91 0.06681 -1.29 0.1980 0.79 1.05 
During Admission Naltrexone Received 0.31 0.1215771 -2.99 0.0030 0.15 0.67 
Pre-Admission OAT Received 15.04 1.143896 35.64 0.0000 12.96 17.46 
Pre-Admission Non-OAT Opioid Prescription Filled 0.48 0.0418063 -8.41 0.0000 0.41 0.57 
Pre-Admission Benzodiazepine Prescription Filled 0.99 0.1243564 -0.1 0.9180 0.77 1.26 
Pre-Admission Naltrexone Received or Prescription Filled 0.27 0.1035082 -3.41 0.0010 0.13 0.57 
Pre-Admission Gabapentin/Pregabalin Prescription Filled 0.89 0.0687118 -1.46 0.1440 0.77 1.04 
Acute OUD Diagnoses Volume 0.98 0.0069802 -2.49 0.0130 0.97 1.00 
Hospital Size Medium (ref. Small) 1.90 0.3410116 3.53 0.0000 1.33 2.69 
Hospital Size Large (ref. Small) 1.91 0.3767839 3.26 0.0010 1.29 2.81 
Census Region Midwest (ref. South) 1.23 0.1970601 1.47 0.1420 0.93 1.71 
Census Region Northeast (ref. South) 1.60 0.2682119 2.81 0.0050 1.15 2.22 
Census Region West (ref. South) 1.63 0.2603606 3.04 0.0020 1.19 2.23 
Admission Volume 1.00 0.0010102 -1.03 0.3010 1.00 1.00 
646 
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